Chinese Journal of Lung Cancer (Jun 2013)

Long-term Survival of A Patient with Advanced Non-small Cell Lung Cancer 
on Bevacizumab Therapy: Case Report and Review of the Literature

  • Wei WU,
  • Junfang TANG,
  • Yuhua WU,
  • Yunzhong ZHU,
  • Liyan XU,
  • Heling SHI,
  • Qiyi MENG,
  • Zan LIU,
  • Lili GUO,
  • Hong TAO,
  • Mingzhi LI,
  • Zhe LIU

DOI
https://doi.org/10.3779/j.issn.1009-3419.2013.06.10
Journal volume & issue
Vol. 16, no. 6
pp. 325 – 329

Abstract

Read online

We report an advanced stage Chinese female lung adenocarcinoma patient who was negative for epidermal growth factor receptor (EGFR), V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutations, also negative for chinodem microtubule-associated protein-like 4/anaplastic lymphoma kinase (EML4-ALK) gene rearrangement and treated with bevacizumab (15 mg/kg) in combination with 6 cycles of conventional doses of paclitaxel and carboplatin chemotherapy. She was then treated with maintenance bevacizumab for a total of 42 cycles, the total dose of bevacizumab is 44,730 mg. The progression-free survival was 39 months. Our findings suggest that maintenance bevacizumab for the treatment of non-small cell lung cancer (NSCLC) is safe and its benefit for long-term survival overwhelms its side effects.

Keywords